Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study (vol 40, pg 3065, 2022).

被引：0
|
作者：
Shen, Lin
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 04期
关键词：
D O I：
10.1200/JCO.23.02629
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：486 / 486
页数：1
相关论文
共 50 条
  • [1] Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
    Shen, Lin
    Kato, Ken
    Kim, Sung-Bae
    Ajani, Jaffer A.
    Zhao, Kuaile
    He, Zhiyong
    Yu, Xinmin
    Shu, Yongqian
    Luo, Qi
    Wang, Jufeng
    Chen, Zhendong
    Niu, Zuoxing
    Zhang, Longzhen
    Yi, Tienan
    Sun, Jong-Mu
    Chen, Jianhua
    Yu, Guohua
    Lin, Chen-Yuan
    Hara, Hiroki
    Bi, Qing
    Satoh, Taroh
    Pazo-Cid, Roberto
    Arkenau, Hendrick-Tobias
    Borg, Christophe
    Lordick, Florian
    Li, Liyun
    Ding, Ningning
    Tao, Aiyang
    Shi, Jingwen
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (26) : 3065 - +
  • [2] Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study
    Ajani, J.
    El Hajbi, F.
    Cunningham, D.
    Alsina, M.
    Thuss-Patience, P.
    Scagliotti, G. V.
    Van den Eynde, M.
    Kim, S-b.
    Kato, K.
    Shen, L.
    Li, L.
    Ding, N.
    Shi, J.
    Barnes, G.
    Van Cutsem, E.
    ESMO OPEN, 2024, 9 (01)
  • [3] RATIONALE 302: Randomized, Phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma
    Van Cutsem, Eric
    Kato, Ken
    Kim, Sung-Bae
    Ajani, Jaffer
    Zhao, Kuaile
    He, Zhiyong
    Yu, Xinmin
    Shu, Yonqian
    Luo, Qi
    Wang, Jufeng
    Chen, Zhendong
    Niu, Zuoxing
    Sun, Jong-Mu
    Lin, Chen-Yuan
    Hara, Hiroki
    Pazo-Cid, Roberto
    Borg, Christophe
    Li, Liyun
    Tao, Aiyang
    Shen, Lin
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (SUPPL 1)
  • [4] Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302
    Hiroki Hara
    Taroh Satoh
    Takashi Kojima
    Takahiro Tsushima
    Yu Sunakawa
    Morihito Okada
    Ningning Ding
    Hongqian Wu
    Liyun Li
    Tian Yu
    Gisoo Barnes
    Ken Kato
    Esophagus, 2024, 21 : 102 - 110
  • [5] RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.
    Shen, Lin
    Kato, Ken
    Kim, Sung-Bae
    Ajani, Jaffer A.
    Zhao, Kuaile
    He, Zhiyong
    Yu, Xinmin
    Shu, Yongqian
    Luo, Qi
    Wang, Jufeng
    Chen, Zhendong
    Niu, Zuoxing
    Sun, Jong Mu
    Lin, Chen-Yuan
    Hara, Hiroki
    Pazo-Cid, Roberto
    Borg, Christophe
    Li, Liyun
    Tao, Aiyang
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302
    Hara, Hiroki
    Satoh, Taroh
    Kojima, Takashi
    Tsushima, Takahiro
    Sunakawa, Yu
    Okada, Morihito
    Ding, Ningning
    Wu, Hongqian
    Li, Liyun
    Yu, Tian
    Barnes, Gisoo
    Kato, Ken
    ESOPHAGUS, 2024, 21 (02) : 102 - 110
  • [7] Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
    Zhao, Kuaile
    Kim, Sung-Bae
    Kato, Ken
    Hsu, Chih-Hung
    Hu, Sheng
    Wang, Feng
    Kojima, Takashi
    Kim, Young Saing
    Van Cutsem, Eric
    Ajani, Jaffer A.
    Li, Liyun
    Ding, Ningning
    Tao, Aiyang
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.
    Zhao, Kuaile
    Kim, Sung-Bae
    Kato, Ken
    Hsu, Chih-Hung
    Hu, Sheng
    Wang, Feng
    Kojima, Takashi
    Kim, Young Saing
    Van Cutsem, Eric
    Ajani, Jaffer A.
    Li, Liyun
    Ding, Ningning
    Tao, Aiyang
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16107 - E16107
  • [9] Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life
    Van Cutsem, E.
    Kato, K.
    Ajani, J.
    Shen, L.
    Xia, T.
    Ding, N.
    Zhan, L.
    Barnes, G.
    Kim, S-B
    ESMO OPEN, 2022, 7 (04)
  • [10] Rational 302: randomized Phase III Trial of Tislelizumab vs. Chemotherapy as Second-line Therapy for advanced unresectable/metastatic Esophageal Squamous Cell Carcinoma
    Moehler, M.
    Shen, L.
    Kato, K.
    Kim, S. B.
    Ajani, J.
    Zhao, K.
    He, Z.
    Yu, X.
    Shu, Y.
    Luo, Q.
    Wang, J.
    Chen, Z.
    Niu, Z.
    Sun, J. M.
    Lin, C. Y.
    Hara, H.
    Pazo-Cid, R.
    Borg, C.
    Li, L.
    Tao, A.
    Cutsem, E. V.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 166 - 166
12345